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Abstract
Despite numerous studies on the role of medial temporal lobe structures in Alzheimer's disease
(AD), the magnitude and clinical significance of amygdala atrophy has been relatively sparsely
investigated. In this study we compared the level of amygdala atrophy to that of the hippocampus
in very mild and mild AD subjects in two large samples (Sample 1 n=90; Sample 2 n=174). Using
a series of linear regression analyses, we investigated whether amygdala atrophy is related to
global cognitive functioning (Clinical Dementia Rating Sum of Boxes: CDR-SB; Mini Mental
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State Examination: MMSE) and neuropsychiatric status. Results indicated that amygdala atrophy
was comparable to hippocampal atrophy in both samples. MMSE and CDR-SB were strongly
related to amygdala atrophy, with amygdala atrophy predicting MMSE scores as well as
hippocampal atrophy, but predicting CDR-SB scores less robustly. Amygdala atrophy was related
to aberrant motor behavior, with potential relationships to anxiety and irritability. These results
suggest that the magnitude of amygdala atrophy is comparable to that of the hippocampus in the
earliest clinical stages of AD, and is related to global illness severity. There also appear to be
specific relationships between the level of amygdala atrophy and neuropsychiatric symptoms that
deserve further investigation.
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1. Introduction
By the time patients exhibit the hallmark amnesic syndrome of Alzheimer's disease (AD),
neuropathology has usually decimated medial temporal lobe (MTL) structures (Braak and
Braak, 1991). In vivo evidence for this process can be plainly seen by viewing magnetic
resonance images. Extensive investigations have demonstrated quantitative morphometric
abnormalities of the hippocampal formation, entorhinal cortex, and perirhinal cortex early in
the illness (prior to dementia). Furthermore, these abnormalities correlate with the overall
severity of clinical impairment and are specifically related to episodic memory deficits (Di
Paola et al., 2007). In post-mortem studies, amyloid (senile) plaques, neurofibrillary tangles,
and neuronal loss have all been observed in the amygdala (Arriagada et al., 1992; Herzog
and Kemper, 1980; Scott et al., 1991; Scott et al., 1992; Tsuchiya and Kosaka, 1990).
Although these post-mortem studies have called attention to similar neuropathological
abnormalities in the amygdala as are found in the hippocampus, there has been far less in
vivo investigation of amygdala atrophy and its clinical correlates in AD.
With respect to amygdala atrophy in early AD, several important anatomic and clinical
questions remain incompletely answered. First, across the 13 published studies of amygdala
atrophy in AD, findings regarding the magnitude of atrophy have been very inconsistent,
with reports of atrophy ranging from 15% to 41% compared to older controls (OC).
Furthermore, it is unclear whether the magnitude of amygdala atrophy is greater than (Basso
et al., 2006; Cuenod et al., 1993; Krasuski et al., 1998; Lehericy et al., 1994; Mori et al.,
1997), less than (Callen et al., 2001; Farrow et al., 2007; Horinek et al., 2006; Jack et al.,
1997), or similar to (Barnes et al., 2006; Killiany et al., 1993; Mizuno et al., 2000; Schultz et
al., 2009) that of the hippocampus. Given the substantial variability in the frequency and
types of socioaffective symptoms in AD, it seems reasonable to hypothesize that the
amygdala would be more variably affected within a sample of AD patients than the
hippocampus. Second, although amygdala atrophy has been shown to relate to global illness
severity in AD (Jack et al., 1997; Mizuno et al., 2000), there has been little investigation
comparing the strength of this relationship with that of the hippocampus. Since the size of
these structures is collinear, it is important to try to understand which of them is most
strongly related to illness severity and whether the amount of atrophy in the other explains
additional variance in overall symptom severity. We hypothesized that hippocampal atrophy
is most strongly related to illness severity but that the amount of amygdala atrophy present
would explain additional variance in illness severity beyond that explained by the
hippocampus. Finally, although behavioral (psychiatric) symptoms are a major contributor
to patient-family dysfunction and distress in AD, there has been surprisingly little effort to
investigate whether amygdala atrophy relates to this domain of symptoms. The only study to
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specifically examine the relation between amygdala atrophy and psychiatric symptoms in
mild AD reported no relationship (Horinek et al., 2006).
In the present study, we used automated MRI-derived measurements of in-vivo human brain
volumes to investigate the magnitude and consistency of amygdala atrophy in two large and
independent samples of patients with AD (and older controls). The main goal of having a
second sample in this study design was to demonstrate the reliability of the findings,
supporting their generalizability. Both samples included a large number of patients with very
mild (CDR = 0.5) and mild (CDR = 1) AD, allowing for measurement of amygdala atrophy
early in the illness. To address the question of whether the amygdala shows comparable
atrophy to the hippocampus, the magnitude and variance of atrophy in the two structures
were compared.
Second, we explored the clinical significance of amygdala atrophy in mild AD, investigating
the relationship between amygdala atrophy and cognitive function using the Mini Mental
State Examination (MMSE) and the Clinical Dementia Rating Scale Sum-of-Boxes (CDR-
SB). In addition, to try to determine the specificity of the relationship, we performed an
additional analysis controlling for hippocampal volume. The goal of these analyses was to
determine whether the magnitude of amygdala atrophy is a reflection of global severity of
the illness and whether it accounts for illness severity beyond its shared variance with
hippocampal atrophy.
Finally, to address questions regarding specific relationships between amygdala atrophy and
types and severity of neuropsychiatric symptoms in AD, data from the Neuropsychiatric
Inventory (NPI) were analyzed. Animal and human studies have suggested that amygdala
lesions are associated with agitation/aggression and irritability (less) (Wright et al., 2007),
anxiety (less)(Davidson, 2002), and apathy (more) (Kile et al., 2009). Data are conflicting in
regard to depression (Omura et al., 2005). We examined the level of amygdala atrophy in
AD patients with either no, mild or moderate/severe impairment using the NPI items
reflecting these symptoms, testing hypotheses based on prior findings as well as exploring
the current data de novo.
2. Method
2.1. Participants
Sample 1—This sample consisted of one hundred eighty AD and OC participants in a
longitudinal study at the Washington University Alzheimer's Disease Research Center,
conducted in accordance with guidelines of the Washington University Human Studies
Committee. There were 177 subjects (60 males and 117 females; mean age 77.4±7.3; mean
education 14.0±2.2). Data from subsets of these subjects have been published in previous
studies (Buckner et al., 2004; Fotenos et al., 2005; Salat et al., 2004). At study enrollment,
subjects with non-AD disorders that could potentially cause dementia, active neurologic or
psychiatric illness, serious head injury, clinical history of stroke, gross anatomical
abnormalities on MRI and use of psychoactive drugs were excluded (Marcus et al., 2007).
Participants underwent detailed structured evaluations, including a health history, depression
inventory, aphasia battery and medication inventory, MMSE, CDR. Diagnostic criteria for
AD required the gradual onset and progression of impairment in memory and in at least one
other cognitive and functional domain, comparable to standard diagnostic criteria for
probable AD (McKhann et al., 1984).
Sample 2—This sample consisted of three hundred sixty-nine AD and OC participants
from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (www.loni.ucla.edu/ADNI).
There were 367 subjects (192 males and 175 females; mean age 75.5±6.2; mean education
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15.5±3.0). The ADNI was launched in 2003 by the NIA, the NIBIB, the FDA, private
pharmaceutical companies and non-profit organizations, as a $60-million, 5-year public-
private partnership. The primary goal of ADNI has been to test whether imaging measures,
biological markers, and clinical and neuropsychological assessment can be combined to
measure the progression of MCI and early AD.
All subjects underwent thorough clinical and cognitive assessment, including MMSE, CDR,
and NPI. The diagnosis of AD was made if the subject had a MMSE score between 20 and
26, CDR score of 0.5 or 1, and met NINCDS/ADRDA criteria for probable Alzheimer's
disease. The OC had MMSE scores between 28 and 30, a global CDR of 0, and no
symptoms of depression, MCI, or other forms of dementia. Subjects were excluded if they
had any serious neurological disease other than incipient AD, any history of brain lesions or
head trauma, or psychoactive medication use. The study was conducted with written
informed consent according to Good Clinical Practice, the Declaration of Helsinki and U.S.
21 CFR Part 50-Protection of Human Subjects, and Part 56-Institutional Review Boards.
2.2. Magnetic resonance imaging data acquisition and analysis
Sample 1—For each subject, multiple (3 or 4) high-resolution structural T1-weighted
magnetization-prepared rapid gradient echo (MP–RAGE) images were acquired entry on a
1.5T Siemens Medical Systems scanner with the following parameters: repetition time (TR)
9.7 ms, echo time (TE) 4 ms, flip angle (FA) 10°, inversion time (TI) 20 ms, voxel size 1 × 1
× 1.25 mm. These data have been made openly available to the scientific community (http://
www.oasis-brains.org/).
Sample 2—For each subject, 2 high-resolution structural T1-weighted MP-RAGE images
were acquired either on a 1.5T General Electric Healthcare, a 1.5T Siemens Medical
Solutions or a 1.5T Phillips Medical System scanner. Acquisition parameters were as
follows: TR 2400 ms, TE minimum full time excitation, FA 8°, TI 1000 ms, voxel size
1.25×1.25×1.2 mm. These data have been made available to the scientific community
(http://www.loni.ucla.edu/ADNI/).
Volumetric analysis was performed using Freesurfer software (http://
surfer.nmr.mgh.harvard.edu) as previously described in detail (Fischl et al., 2002). Briefly,
for each subject, the multiple structural scans were motion corrected and averaged to create
a single volume. The resulting averaged volume was used to segment cerebral white matter
and deep gray matter structures (including hippocampus and amygdala). This segmentation
procedure automatically assigned a neuroanatomical label to each voxel in an MRI volume
based on probabilistic information automatically estimated from a manually labeled training
set. This probability is based on the voxel's location in the volume, the neighboring voxels'
tissue classes, and the intensity value in each voxel. The technique has previously been
shown to be comparable in accuracy to manual labeling (Fischl et al., 2002). For each
subject, we visually inspected the segmentation of the amygdala and determined whether it
was acceptable according to standard anatomic criteria as we have employed in prior studies
(Wright et al., Biol Psych, 2007). This process resulted in the exclusion of 3 subjects (AD
patients) from Sample 1 and 2 subjects (AD patients) from Sample 2, all of whom had poor
segmentations that underestimated the volume of the amygdala. For the purposes of optimal
reproducibility, we chose to exclude the scans of these individuals rather than manually edit
them.
MRI data were used to calculate adjusted amygdala and hippocampus volumes as follows.
Right and left amygdala (r=0.849) and right and left hippocampi (r=0.926) were averaged
into one single amygdala and one single hippocampal volumetric measure per subject. To
adjust for differences in head size, each subject's average amygdala and hippocampal
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volumes were divided by the subject's total intracranial volume (TIV)(Jenkins et al., 2000)
and then multiplied by the sample's mean TIV (Callen et al., 2001).
2.3. Statistical analysis
The magnitude of amygdala atrophy was calculated as [(1 - AD subject adjusted amygdala)/
OC mean adjusted amygdala] and then averaged for all AD subjects (a similar computation
was performed for the hippocampus). We used the t statistic for the various group
comparisons of the magnitude of amygdala and hippocampal atrophy. To estimate the effect
size of AD on amygdala and hippocampus, Cohen's d was calculated for each sample. In
addition, we calculated a coefficient of variation for amygdala and hippocampal volumes of
AD subjects by dividing the standard deviation of the structure's volume by the mean
volume for each sample.
Both cognitive and neuropsychiatric data were available for Sample 2 only: statistical
analyses were performed on this sample. Using a series of linear regressions, we then
examined whether amygdala atrophy predicted degree of cognitive function (MMSE and
CDR-SB). We performed the analyses twice, first controlling for the demographic variables
age, education and gender, and then also for hippocampal volume. In addition, we also
selected 5 neuropsychiatric items from the NPI for hypothesis-driven analysis of select
symptoms: 1) agitation/aggression, 2) depression/dysthymia, 3) anxiety, 4) apathy/
indifference, 5) irritability, and we performed exploratory analyses of the other NPI
variables. In these regression analyses, amygdala volumes served as the dependant variable
and NPI items the predictors. Because the predictors are categorical (ordinal), NPI items
were converted to dummy variables, allowing us to compare amygdala volumes at three
levels of symptom severity: 0 (absent), 1 (mild), and 2 (moderate). There were too few
patients with NPI scores of 3 to perform specific analyses.
Analyses of variance and chi-square analyses were used to compare groups on quantitative
continuous and on categorical demographic variables respectively. All tests of statistical
significance were 2-tailed, and were considered significant at P<0.05 and trend-level at
P<0.1.
3. Results
In Sample 1, AD and OC groups were equivalent in age (P=0.653) but there were more men
in the AD (41%) versus the OC (26%) groups (χ2=4.2, df=2, P=0.041) and the education
level was lower in the AD (13.7±2.2) versus the OC (14.4±2.2) groups (t=2.12, df=178,
P=0.035). In Sample 2, AD and OC groups did not differ in age (P=0.945) or sex (P>0.93)
but the education level was lower in the AD (14.8±3.1) versus the OC (16.2±2.8) groups
(t=4.65, df=367, P<0.001). Demographic and clinical data are presented in Table 1.
Table 2 presents volumetric data for amygdala and hippocampus for AD and OC. Amygdala
atrophy was substantial in subjects with very mild to mild AD. In Sample 1, the magnitudes
of amygdala and hippocampal atrophy (compared to OC) were equivalent (P=0.3); in
Sample 2, amygdala atrophy was slightly less prominent than hippocampal atrophy (t=3.40,
df=175, P=0.0008). The effect size (Cohen's d) of AD on amygdala and hippocampus was
respectively 1.0 and 1.0 for Sample 1 and 1.5 and 1.7 for Sample 2. The coefficients of
variation for adjusted amygdala volume (Sample 1 = 19.3%; Sample 2 = 18.5%) were
comparable to the coefficients of variation of adjusted hippocampus volume (Sample 1 =
18.3%; Sample 2 = 19.1%), indicating that there was similar variance in both structures in
these patients. Figure 2 provides details on amygdala and hippocampal atrophy (cross-
sectionally to clinical data acquisition).
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Amygdala atrophy and hippocampal atrophy strongly paralleled each other at different
levels of dementia severity and were essentially comparable at every level of the very mild
to mild severity spectrum of the disease. These relationships are illustrated in Figures 3a and
3b. At CDR 0.5 (n=157, combining across samples), amygdala atrophy (-16.5%) was
comparable to hippocampal atrophy (-17.2%) (P=0.5). At CDR 1 (n=107), amygdala
atrophy (-23.5%) was slightly less prominent than hippocampal atrophy (-26.5%) (t=2.4,
df=106, P=0.01).
In linear regression analyses, amygdala volumes predicted scores on the MMSE (r=0.24,
P=0.001) with a similar magnitude of correlation as hippocampal volumes (r=0.25,
P<0.001). In contrast, amygdala volume was less strongly associated with CDR-SB (r=0.27,
P<0.0003) than was the hippocampus (r=0.37, P<0.0000006). In linear regression analyses,
amygdala volumes did not explain additional variance in the MMSE (regression equation
r=0.27, P=0.001; β=0.135, delta r2=0.01, P=0.163) or in CDR-SB scores (regression
equation r=0.37, P<0.000003; β=-0.059, delta r2=0.002, P=0.531) over and above
hippocampal volumes.
There was no association between amygdala and any of the 5 targeted neuropsychiatric
symptom domains (agitation/aggression, depression/dysthymia, anxiety, apathy/indifference,
irritability), although exploratory analyses suggested several possible relationships worthy
of future exploration. In post hoc exploratory analyses, greater amygdala atrophy was
associated with more prominent aberrant motor behavior (AMB) (F=4.45, df=175, P=0.01;
see Figure 4c), but not with scores on other NPI items (delusions, hallucinations, euphoria/
elation, disinhibition, sleep and appetite; all P values>0.1). Figures 4a and 4b illustrates the
interesting potential relationships with anxiety and irritability, suggesting that subjects with
greater anxiety (OC=1379±187; AD NPI anxiety: 2=1152±158, 1=1066±199, 0=1095±208)
and irritability (OC=1379±187; AD NPI anxiety: 2=1122±162, 1=1068±177, 0=1098±218)
might have less amygdala atrophy. Although these relations did not reach conventional
levels of statistical significance, AD with NPI anxiety = 2 showed trend level significantly
higher amygdala volume compared to NPI anxiety = 1 (one-sided t=1.382, df=173,
P=0.085). Finally, neither the amygdala (r=0.080, P=0.292) nor the hippocampal volumes
(r=0.020, P=0.796) were related to the NPI global score.
4. Discussion
To date, the magnitude and consistency of amygdala atrophy early in the course of AD
dementia has been unclear, with conflicting reports in the literature. The results of this study
help to resolve this issue by showing that amygdala atrophy is comparable to hippocampal
atrophy in two very large, independent samples of very mild and mild AD dementia patients.
Furthermore, the magnitude of amygdala atrophy is related to the severity of cognitive
impairment (as measured by MMSE and CDR-SB), even at these early stages of dementia.
With regard to neuropsychiatric symptoms, greater amygdala atrophy is seen in patients with
more aberrant motor behavior, and there are also possible relationships with anxiety and
irritability (both being suggestively associated with a lesser degree of amygdala atrophy).
The literature comparing the magnitude of amygdala vs. hippocampal atrophy in AD
contains heterogeneous results. The variability in findings is likely due to small samples, the
inclusion of AD patients at varying stages of the illness (not just mild), and varying
measurement techniques and anatomic boundary criteria (Barnes et al., 2006; Horinek et al.,
2006; Schultz et al., 2009). The large sample sizes and similar characteristics of subjects in
the present investigation, as well as the uniformity of volumetric measurement techniques,
allow for a more definitive comparison of amygdala and hippocampal atrophy, and indicate
that both of these MTL structures are similarly and consistently affected in the mildest
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clinical stages of AD dementia. Of note, Figure 2 suggests less hippocampal atrophy and
amygdala atrophy in AD subjects from sample 1 (WU) in comparison to AD subjects from
sample 2 (ADNI). The most likely explanation for this is that AD subjects from sample 2
may be slightly more clinically impaired (in Sample 1, mean MMSE = 24.6 and 30% were
CDR 1 (as opposed to CDR 0.5); in Sample 2, mean MMSE = 23.3 and 48% were CDR 1).
Post-mortem studies have shown that amygdala atrophy in AD is prominent (Scott et al.,
1991) and is associated with substantial neuronal loss (Scott et al., 1992). Both plaque and
tangle pathology affect the amygdala in cases who die at mild stages of the illness, and to a
generally similar degree as that of the hippocampus (Arriagada et al., 1992; Price et al.,
1991; Price and Morris, 1999). Significant decreases in cell packing density have been
observed in all divisions of the amygdala (Herzog and Kemper, 1980) although the
basolateral complex (lateral, basal and accessory basal nuclei) seems more particularly
affected by neurofibrillary tangles and neuropil threads as early as neuropathological stage II
(Braak and Braak, 1991). This region is reciprocally connected to the hippocampus and
frontotemporal cortical regions (Scott et al., 1991).
The consistency of amygdala and hippocampal atrophy, along with their known
connectivity, suggests that pathology in both of these MTL structures could contribute to the
characteristic cognitive and behavioral changes of mild AD. Several studies have reported
on the relation between amygdala and measures of global cognitive functioning such as the
MMSE (Basso et al., 2006; Cuenod et al., 1993; Deweer et al., 1995; Horinek et al., 2006;
Laakso et al., 1995) and the CDR (Jack et al., 1997; Mizuno et al., 2000) in AD and its
prodromal phase (mild cognitive impairment)(Kovacevic et al., 2009). Since the level of
hippocampal atrophy has been shown in many studies to be strongly and consistently related
to the severity of impairment in AD, and since the level of amygdala atrophy is correlated
with that of the hippocampus, it would be of interest to know which explains the most
variance in impairment and to what degree the other explains additional, unique variance.
None of the prior studies have made these direct comparisons. Our results indicate that,
although amygdala volume alone correlates with cognitive impairment, the magnitude of
amygdala atrophy does not account for additional variance in measures of illness severity
(MMSE; CDR-SB) beyond its shared variance with the hippocampus. Further support for
this finding was provided by a prior longitudinal study of non-demented elderly which
demonstrated that, while amygdala atrophy predicts conversion to AD, it is a less powerful
predictor than hippocampal atrophy (den Heijer et al., 2006).
The present results also indicate that amygdala atrophy relates to certain aspects of
neuropsychiatric status in mild AD. Mild aberrant motor behaviors were associated with
relatively preserved amygdala volume and moderate/severe AMB were associated with
significant amygdala atrophy. AMB represents repetitive purposeless behaviors such as
fidgeting, wandering, pacing or rummaging. Although AMB are relatively frequent in AD
(Mega et al., 1996), there has been no report of their neuroanatomical correlates in AD. In a
mixed dementia group including AD and frontotemporal dementia, AMB were associated
with reduced grey matter density in the dorsal anterior cingulate and supplementary motor
area, but these effects were mostly driven by the frontotemporal dementia patients in the
group and there were no findings associated with grey matter density in the amygdala
(Rosen et al., 2005). In addition to Kluver-Bucy syndrome, bilateral lesions of the amygdala
in primates have been related to stereotyped behaviors (repetitive and purposeless behaviors)
such as rocking or self-biting (Bauman et al., 2008), which may be broadly similar to some
types of AMB in AD. Future studies would benefit from more detailed characterization of
the types and severity of AMB in AD, and from studies of other anatomic structures that
may be involved (e.g., basal ganglia).
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Finally, our study provides preliminary results suggesting that anxiety and irritability could
be associated with relatively preserved amygdala volume in AD. Of note, no hypertrophy
was evidenced as the mean amygdala volume at every anxiety and irritability severity level
was well below the mean amygdala volume in OC. This possible association between NPS
and relatively preserved amygdala volume deserves additional investigation. Structural and
functional neuroimaging studies have indicated that there is a relationship between the
amygdala and anxiety-related behaviors in healthy individuals in those with primary anxiety
disorders. Increased amygdala activation has been observed in several anxiety-provoking
paradigms in these populations (Rauch et al., 2003). In normal young girls, larger amygdala
volume correlates with greater fearfulness (van der Plas et al.). Generalized anxiety disorder
has been associated with amygdala hypertrophy (Schienle et al.). Human amygdala lesions
are, at times, associated with a reduction in the experience of fear (Tranel et al., 2006) and
lack of emotional arousal to negative stimuli (Berntson et al., 2007). The amygdala appears
to play a crucial role in learning of new stimulus-threat contingencies and in the expression
of cue-specific fear (Davidson, 2002). It is intriguing to speculate that, in the setting of
reduced ability to interpret the environment and regulate emotional responses (due to
memory, executive, and other cognitive impairment), AD patients with relatively preserved
amygdala function may exhibit heightened and possibly less differentiated emotional
responses that seem inappropriate to caregivers, such as anxiety and irritability.
The main limitation in the present investigation concerns the assessment of neuropsychiatric
symptoms with the NPIQ. Ascertainment and quantification of behavioral disturbances are
more reliably performed using diagnostic interviews, and many other more refined
questionnaire-based instruments are also available for psychiatric symptoms. Although such
approaches are difficult to implement in a large study like ADNI, smaller prospective
studies could be designed to follow up on preliminary observations reported here between
the amygdala and AMB, anxiety, and irritability. A second limitation concerns the
volumetric measurement with automated segmentation techniques, which although highly
reliable may not have been quite as accurate as detailed manual tracing, which is still
considered the gold standard. However, this method is highly time consuming and would
have been difficult to perform in samples as large as those in this study. Finally, we focused
specifically on the amygdala and hippocampus in this study but future studies should
investigate the possible relationships of amygdala atrophy with atrophy in cortical and/or
subcortical structures and their collective contributions to cognitive and behavioral status in
AD.
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Figure 1. Example brain segmentations from a subject with Alzheimer's disease and an older
control subject
AD: Alzheimer's disease; OC: older control
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Figure 2. The magnitude of amygdala atrophy is similar to that of hippocampal atrophy in early
Alzheimer's disease
ADNI: Alzheimer's disease neuroimaging initiative; WU: Washington University
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Figure 3. Amygdala and hippocampal atrophy relate to MMSE scores and CDR-SB in very mild
to mild AD
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Figure 4. Relationships between amygdala volume and specific neuropsychiatric symptoms in
AD, including irritability, anxiety, and aberrant motor behavior
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